The uplist, finalizing the deal with AMBS / Breakthrough DX and closing the deal with Provista and their lab is all happening "at once".
Why close the follow through with the extra percentage, purely financial.
They were waiting on the Independent valuation to see if TODOS was going to complete the deal.
They got it and from what I understand it came in either expected or better than expected.
I see buying the rest will be far less expensive upfront than down the road. AMBS will be (could potentially) be in the driver's seat on what the rest of that percentage would cost later in the year.
I think, and this is only me reading into things, that the valuation is strong, the results are looking good from Dr.
Arendt and the relationship with Dr. Chung are strong motivating factors to close the full deal once they can.
April 9, 2020
Acquisition of Breakthrough Diagnostics, Inc. for Alzheimer’s blood diagnostic LymPro Test™
The Company has been seeking to complete the acquisition of Breakthrough Diagnostics due to the tremendous potential of the LymPro Test™ as a diagnostic blood test for Alzheimer’s disease. We have commissioned an independent third-party valuation of LymPro in order to fulfill the necessary requirements to complete the acquisition later this quarter. We believe that a blood test for Alzheimer’s disease remains one of the most elusive and valuable diagnostic tests sought by medical professionals. We further believe that our solution may fundamentally impact how we address Alzheimer’s disease by allowing for early diagnosis and early enrollment into clinical trials. It may also assist in the development of new therapeutic strategies that have greater success in treating Alzheimer’s disease at its earliest stages, prior to significant brain damage.
https://investor.todosmedical.com/news-events...ate-update
Todos Medical Appoints Dr. Lauren Chung to its Board of Directors
APRIL 17, 2020 7:30AM EDT
Receives valuation of Alzheimer’s disease blood diagnostic LymPro Test Retains Donohoe Advisors to assist with Nasdaq CM™ listing process
***Dr. Chung serves on the business review board of the Alzheimer’s Drug Discovery Foundation
Todos Medical also announces it has received the independent third-party valuation report required to complete the full acquisition of its joint venture Breakthrough Diagnostics, Inc. that is developing the proprietary immune-based Alzheimer’s disease blood diagnostic LymPro Test. Additionally, the Company announces that it has retained Donohoe Advisors to assist with its proposed listing on the Nasdaq CM™ national stock exchange in the United States.
https://investor.todosmedical.com/news-events...s-board-of
As a side note, I'm still really curious about ELTO Pharma. Gerald separated that out from the deal with EMOR. So, that leaves that a very nice opportunity to deal with.
Aloha
Why close the follow through with the extra percentage, purely financial.
They were waiting on the Independent valuation to see if TODOS was going to complete the deal.
They got it and from what I understand it came in either expected or better than expected.
I see buying the rest will be far less expensive upfront than down the road. AMBS will be (could potentially) be in the driver's seat on what the rest of that percentage would cost later in the year.
I think, and this is only me reading into things, that the valuation is strong, the results are looking good from Dr.
Arendt and the relationship with Dr. Chung are strong motivating factors to close the full deal once they can.
April 9, 2020
Acquisition of Breakthrough Diagnostics, Inc. for Alzheimer’s blood diagnostic LymPro Test™
The Company has been seeking to complete the acquisition of Breakthrough Diagnostics due to the tremendous potential of the LymPro Test™ as a diagnostic blood test for Alzheimer’s disease. We have commissioned an independent third-party valuation of LymPro in order to fulfill the necessary requirements to complete the acquisition later this quarter. We believe that a blood test for Alzheimer’s disease remains one of the most elusive and valuable diagnostic tests sought by medical professionals. We further believe that our solution may fundamentally impact how we address Alzheimer’s disease by allowing for early diagnosis and early enrollment into clinical trials. It may also assist in the development of new therapeutic strategies that have greater success in treating Alzheimer’s disease at its earliest stages, prior to significant brain damage.
https://investor.todosmedical.com/news-events...ate-update
Todos Medical Appoints Dr. Lauren Chung to its Board of Directors
APRIL 17, 2020 7:30AM EDT
Receives valuation of Alzheimer’s disease blood diagnostic LymPro Test Retains Donohoe Advisors to assist with Nasdaq CM™ listing process
***Dr. Chung serves on the business review board of the Alzheimer’s Drug Discovery Foundation
Todos Medical also announces it has received the independent third-party valuation report required to complete the full acquisition of its joint venture Breakthrough Diagnostics, Inc. that is developing the proprietary immune-based Alzheimer’s disease blood diagnostic LymPro Test. Additionally, the Company announces that it has retained Donohoe Advisors to assist with its proposed listing on the Nasdaq CM™ national stock exchange in the United States.
https://investor.todosmedical.com/news-events...s-board-of
As a side note, I'm still really curious about ELTO Pharma. Gerald separated that out from the deal with EMOR. So, that leaves that a very nice opportunity to deal with.
Aloha
